Jasper Therapeutics Inc (JSPRW NASDAQ) stock market data APIs
$0.013
-0(-0%)
as of July 2, 2026
Try our APIs with
free plan!
Jasper Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Prev. Close
0.013
Open
0.0102
High
0.013
Low
0.0102
52 wk Range
0.0101-0.1475
Market Cap
0
EPS
-0.687
Beta
3.074
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Jasper Therapeutics Inc data using free add-ons & libraries
Get Jasper Therapeutics Inc Fundamental Data
Jasper Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -69 935 000
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-09-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Jasper Therapeutics Inc News
New
Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the 8 Most Oversold Penny Stocks to Buy Right Now. On April 1, 2026, Evercore ISI lowered the price target on Jasper Therapeutics, Inc. (NASDAQ:JSPR...
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the penny stocks with the potential to rise 1000percent. UBS initiated coverage of Jasper Therapeutics on March 23, 2026, with a Neutral rating and a...
Get Jasper Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
